Precision IBD

About Precision IBD

Precision IBD, Inc. was established in 2016 as a biopharmaceutical company with a sharp focus on inflammatory bowel disease (IBD). The company was co-founded by Scott Glenn, a serial entrepreneur in the biotech space. A significant milestone occurred in June 2019 when Precision IBD acquired Prometheus Laboratories, a gastrointestinal diagnostics unit, from Nestlé Health Science for $35 million. Following this acquisition, the company underwent a strategic rebranding in September 2019, changing its name to Prometheus Biosciences, Inc. to reflect a broader focus on applying precision medicine to gastroenterology and autoimmune diseases. Mark C. McKenna, a former executive at Salix Pharmaceuticals, was appointed CEO during this transition, with Scott Glenn remaining on the board.

Prometheus Biosciences operated on the principle of precision medicine, aiming to move beyond the "one-size-fits-all" treatment approach for IBD. The company's core was its proprietary platform, Prometheus360, which utilized a vast biobank and gastrointestinal database, licensed from Cedars-Sinai Medical Center, containing over 20,000 patient samples collected over two decades. By applying machine learning to this data, the firm worked to discover and develop targeted therapies and companion diagnostics. This approach was designed to identify specific patient subpopulations who would be most likely to respond to a particular treatment, thereby accelerating clinical development and improving patient outcomes. One of its key drug candidates, PRA023, targeted TL1A, a protein linked to intestinal inflammation and fibrosis.

The company's business model revolved around the discovery, development, and eventual commercialization of this portfolio of precision therapeutics and companion diagnostics. This strategy attracted significant investment, including a $130 million financing round in November 2020. The firm went public in March 2021, raising $190 million in its IPO. The journey of Precision IBD, rebranded as Prometheus Biosciences, culminated in a major acquisition in April 2023, when Merck acquired the company for approximately $10.8 billion, recognizing the potential of its lead drug candidate and its precision medicine platform to revolutionize the treatment of IBD and other autoimmune diseases.